SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
StreetBrief Valuation Model
AGN
|
|
|
+2.89%
in
26 days
This long selection has only a little more room to hit our target, but it will be driven by sector news, so it may overshoot.
|
New Indexes to Track Healthcare Trends and More
AGN
|
|
|
+7.68%
in
98 days
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
FDA Calendar: Allergan's New Rx for Eyelashes
AGN
|
|
|
+47.99%
in
218 days
(closed on 08/04/09)
<> 
The accompanying table [click to enlarge] includes an updated FDA calendar of 65 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with six companies listed in red with overdue decisions and the possibility for five decisions during the coming week. Click here for my previous FDA calendar articles and below is a review of recent decisions + a preview of the coming week:
1.) Allergan (AGN) received FDA approval on Friday for Latisse (bimatoprost solution 0.0...
|
Allergan Wants To Improve Your Eyelashes
AGN
|
|
|
-6.59%
in
22 days
(closed on 12/28/08)
<> 
<> The accompanying table [click to enlarge] presents an updated calendar of 74 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>< />< /><>< />< /><>...
|
Cosmetic & Reconstructive Medicine: An Industry Profile
AGN
|
|
|
-1.57%
in
55 days
(closed on 12/06/08)
|
From the Blogosphere
Earnings highlights: Aetna, Allergan, E*Trade, Goodyear, RadioShack, SAP, Visa ...
Filed under: Earnings reports, Allergan (AGN), Aetna Inc (AET), TD AmeriTrade Holding (AMTD), RadioShack Corp (RSH), Goodyear Tire and Rubber (GT), E*TRADE (ETFC), Visa Inc. (V) Here are some highlights from last week's earnings coverage from BloggingStocks: <> Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher. Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher. Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged. <>Cabot Oil & Gas Corp. (NYSE: COG) r...
|
Pharma earnings recap: Mylan, Allergan, Novo-Nordisk
Filed under: Earnings reports, Allergan (AGN)  One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.
<>On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cen...
|
Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
|
The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Economics:8:30am ET<ul<li>GDP - Street Sees 3.2%<>Initial Claims - Street Sees 525KEarnings:ABB (NYSE: ABB) – consensus EPS $0.30Acme United (NYSE: ACU) – consensus EPS $0.39Aetna Inc. (NASDAQ: AET) – consensus EPS $0.66AGL Resource (NYSE: AGL) – consensus EPS $0.23Agree Realty (NYSE: ADC) – consensus EPS $0.69Airgas (NYSE: ARG) – consensus EPS $0.67Airvana (NASDAQ: AIRV) – consensus EPS $0.22Alexander & Baldwin (NASDAQ: ALEX) – consensus EPS $0.28Allegheny Energy, I...
|
Spectrum Pharmaceuticals: Rumors of Buyout Talks Persist
<font>An unconfirmed rumor about a possible Spectrum Pharmaceuticals ( SPPI) buyout was reported by </font> <font>TheFlyontheWall</font><font> during Friday's session. This rumor also supports the ongoing speculation that SPPI could be acquired by a larger specialty drug maker following two drug reviews scheduled this fall.</font> - <font>September 7: Zevalin </font>
- <font>October 8: Fusilev</font>
<font>After a brief pullback last week, shares of SPPI are likely to continue their advance heading into the coming week:</font>
<font>TIMELINE</font> <font> </font> <><font>I firs...
|
Who Will Buy Spectrum Pharmacueticals?
<>There seems to be a lot of speculation on the chances of Spectrum Pharma (SPPI) being acquired over the coming months. I personally don't think it will happen, but there are a few companies that could be interested. Bayer (BYERF.PK) will always be mentioned because of the fact they sell Zevalin in Europe, but Bayer did just divest two oncology drugs to Genzyme (GENZ), Fludara and Leukine, which makes me think that oncology is not where they want to focus their company. Allergan (AGN) should also be mentioned because of their partnership of bladder cancer drug EOquin with Spectrum, the drug...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Allergan Inc.
- Answers.com
